Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CapsoVision, Inc. ( (CV) ) has shared an update.
On September 22, 2025, CapsoVision, Inc. announced the planned retirement of Rebecca Petersen, its Senior Director of Clinical Affairs, effective October 15, 2025. Keri Jorgenson has been promoted to Director of Clinical Operations and will lead the clinical development operations, ensuring a seamless transition. Petersen will continue to support the company through a consulting agreement starting October 16, 2025, to facilitate a smooth transition without disrupting operations.
The most recent analyst rating on (CV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.
More about CapsoVision, Inc.
Average Trading Volume: 247,173
Learn more about CV stock on TipRanks’ Stock Analysis page.